Asuragen, UC-Davis MIND Institute Publish Study Vetting PCR-Based Assay for Fragile X Mutations
March 04, 2010
Asuragen, UC-Davis MIND Institute Publish Study Vetting PCR-Based Assay for Fragile X Mutations
The method is currently available from Asuragen as a research-use-only PCR kit, but the company is hoping that the publication is an important step toward developing a routine PCR-based diagnostic for the disorder.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Asuragen Presents Data Backing New Molecular Test as Better Predictor of Fragile X Risk in Offspring
March 21, 2013 / PCR Insider - Dx Focus: CDC's Dengue Fever Assay; Asuragen Grants BD License to Armored RNA Tech
June 21, 2012 / PCR Insider - Finnish Team Develops Multiple Heat Pulse PCR Method for Amplification of GC-Rich Regions
January 19, 2012 / PCR Insider - Asuragen Using NICHHD Grant to Adapt Fragile X MDx Assay for Newborn Screening
October 6, 2011 / PCR Insider - Quest Pulls Ahead in Fragile X Test Race with NY State DoH Approval
July 29, 2010 / PCR Insider